PATENT CLAIM ANALYSIS

Application Number: 15898016
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "089000"]

Abstract:
The present disclosure provides for the administration of β-NMN, which increases the secretion of adiponectin. The present disclosure also provides an adiponectin secretion enhancer comprising β-nicotinamide mononucleotide, a pharmaceutically acceptable salt thereof or a solvate thereof, and a dietary supplement containing the aforementioned secretion enhancer, which can he ingested in order to increase the secretion of adiponectin. Also disclosed are methods of treating insulin resistance-related diseases such as of metabolic syndrome, diabetes, hyperlipidemia, fatty liver disease, hypertension, obesity, and arteriosclerosis.

Claim (Index 1):
An adiponectin secretion enhancer comprising \u03b2-nicotinamide mononucleotide (\u03b2-NMN), a pharmaceutically acceptable salt thereof, or a solvate thereof.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 88.0
- Lexical Diversity: 1.55
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['11542790', '14855293', '15783845', '14434573', '13510815']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7069433328547229
- 35 USC 102 Novelty (BERT): 0.5175384595184518
- Combined Prediction Score: 0.6880028455210958
- Mean Citation Score: 268.196012
- Max Citation Score: 291.7117
- Similarity Product: 217.50185620573163

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test